bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 1 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
Authors: Pedersen Malin , Küsters-Vandevelde Heidi V.N. , Viros Amaya , Groenen Patricia J.T.A. , Sanchez-Laorden Berta , Gilhuis Jacobus H. , van Engen-van Grunsven Ilse A. , Renier Willy , Schieving Jolanda , Niculescu-Duvaz Ion , Springer Caroline J. , Küsters Benno , Wesseling Pieter , Blokx Willeke A.M. , Marais Richard
Published: April 2023

Supplementary Figure 1 PDF file - 795K, Data are presented to show that NRASG12D does not induce melanoma when expressed in the melanocytes of adult mice
Supplementary Table 5 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Authors: Grabiner Brian C. , Nardi Valentina , Birsoy Kıvanç , Possemato Richard , Shen Kuang , Sinha Sumi , Jordan Alexander , Beck Andrew H. , Sabatini David M.
Published: April 2023

XLSX file 17K, All site-directed mutagenesis primers to generate mutant mTOR and Rheb1 are listed
Supplementary Table 3 from MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction
Authors: Asmussen Jennifer , Lasater Elisabeth A. , Tajon Cheryl , Oses-Prieto Juan , Jun Young-wook , Taylor Barry S. , Burlingame Alma , Craik Charles S. , Shah Neil P.
Published: April 2023

XLSX file 43K, K562 induction of apoptosis in response TKI and cytokine treatment
Supplementary Table 1 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Authors: Grabiner Brian C. , Nardi Valentina , Birsoy Kıvanç , Possemato Richard , Shen Kuang , Sinha Sumi , Jordan Alexander , Beck Andrew H. , Sabatini David M.
Published: April 2023

XLSX file 89K, All mutations from the cBIO and COSMIC databases in mTOR pathway genes, excluding MTOR, are listed
Supplementary Information from Inflammation-Induced NFATc1–STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by KrasG12D
Authors: Baumgart Sandra , Chen Nai-Ming , Siveke Jens T. , König Alexander , Zhang Jin-San , Singh Shiv K. , Wolf Elmar , Bartkuhn Marek , Esposito Irene , Heßmann Elisabeth , Reinecke Johanna , Nikorowitsch Julius , Brunner Marius , Singh Garima , Fernandez-Zapico Martin E. , Smyrk Thomas , Bamlet William R. , Eilers Martin , Neesse Albrecht , Gress Thomas M. , Billadeau Daniel D. , Tuveson David , Urrutia Raul , Ellenrieder Volker
Published: April 2023

PDF file 184K, This file contains Supplementary Methods, Tables (referring to the human TMA analyses as shown in Figure 3) and Supplementary References
Supplementary Figure 4 from Inflammation-Induced NFATc1–STAT3 Transcription Complex Promotes Pancreatic Cancer Initiation by KrasG12D
Authors: Baumgart Sandra , Chen Nai-Ming , Siveke Jens T. , König Alexander , Zhang Jin-San , Singh Shiv K. , Wolf Elmar , Bartkuhn Marek , Esposito Irene , Heßmann Elisabeth , Reinecke Johanna , Nikorowitsch Julius , Brunner Marius , Singh Garima , Fernandez-Zapico Martin E. , Smyrk Thomas , Bamlet William R. , Eilers Martin , Neesse Albrecht , Gress Thomas M. , Billadeau Daniel D. , Tuveson David , Urrutia Raul , Ellenrieder Volker
Published: April 2023

PDF file 1592K, Supplementary Figure 4 refers to Figure 4 and provides additional information about the ChIP-Seq analysis performed in KrasG12D;NFATc1 primary cancer cell lines
Supplementary Figure 2 from RNA Helicase A Is a Downstream Mediator of KIF1Bβ Tumor-Suppressor Function in Neuroblastoma
Authors: Chen Zhi Xiong , Wallis Karin , Fell Stuart M. , Sobrado Veronica R. , Hemmer Marie C. , Ramsköld Daniel , Hellman Ulf , Sandberg Rickard , Kenchappa Rajappa S. , Martinson Tommy , Johnsen John I. , Kogner Per , Schlisio Susanne
Published: April 2023

PDF file 3837K, Figure S2, related to Figure 2. DHX9 is required for KIF1Bbeta-induced apoptosis
Supplementary Table 3 from Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma
Authors: Sangaletti Sabina , Tripodo Claudio , Vitali Caterina , Portararo Paola , Guarnotta Carla , Casalini Patrizia , Cappetti Barbara , Miotti Silvia , Pinciroli Patrizia , Fuligni Fabio , Fais Franco , Piccaluga Pier Paolo , Colombo Mario P.
Published: April 2023

PDF file 45K, List of data sets and case sconsidered for human GEP analysis
Supplementary Text from Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Authors: de Bruin Elza C. , Cowell Catherine , Warne Patricia H. , Jiang Ming , Saunders Rebecca E. , Melnick Mary Ann , Gettinger Scott , Walther Zenta , Wurtz Anna , Heynen Guus J. , Heideman Daniëlle A.M. , Gómez-Román Javier , García-Castaño Almudena , Gong Yixuan , Ladanyi Marc , Varmus Harold , Bernards René , Smit Egbert F. , Politi Katerina , Downward Julian
Published: April 2023

PDF file 180K, Supplementary experimental procedures Supplementary table and figure legends Supplementary references
Supplementary Table 1 from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
Authors: Domchek Susan M. , Tang Jiangbo , Stopfer Jill , Lilli Dana R. , Hamel Nancy , Tischkowitz Marc , Monteiro Alvaro N.A. , Messick Troy E. , Powers Jacquelyn , Yonker Alexandria , Couch Fergus J. , Goldgar David E. , Davidson H. Rosemarie , Nathanson Katherine L. , Foulkes William D. , Greenberg Roger A.
Published: April 2023

Supplementary Table 1 PDF file 38K, This table summarizes all additional V1736A pedigrees
Supplementary Methods from Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
Authors: Domchek Susan M. , Tang Jiangbo , Stopfer Jill , Lilli Dana R. , Hamel Nancy , Tischkowitz Marc , Monteiro Alvaro N.A. , Messick Troy E. , Powers Jacquelyn , Yonker Alexandria , Couch Fergus J. , Goldgar David E. , Davidson H. Rosemarie , Nathanson Katherine L. , Foulkes William D. , Greenberg Roger A.
Published: April 2023

Supplementary Methods PDF file 61K, This document describes the methods for all supplemental data
Supplementary Figures S1 - S2 from Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
Authors: van Kruchten Michel , de Vries Elisabeth G. , Glaudemans Andor W. , van Lanschot Meta C. , van Faassen Martijn , Kema Ido P. , Brown Myles , Schröder Carolien P. , de Vries Erik F. , Hospers Geke A.
Published: April 2023

Supplemental Figure S1. (A) Patient plasma fulvestrant levels at day 28 and 84 as measured by LC/MS/MS. (B) Patient serum estradiol (E2) levels at baseline, day 28 and 84, measured by fluorescent-immuno-assay and corrected for fulvestrant cross-reactivity. Supplemental Figure S2. Cross-reactivity between fulvestrant and estradiol (E2) fluorescent-immuno-assay.
Supplementary Tables 1,2,3 from Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Authors: Herrera-Abreu Maria Teresa , Pearson Alex , Campbell James , Shnyder Steve D. , Knowles Margaret A. , Ashworth Alan , Turner Nicholas C.
Published: April 2023

Supplementary Tables 1,2,3 - PDF file 283K, Details of cell lines included in siRNA screen and processed data from screen
Supplementary Figure 7 from Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Authors: Herrera-Abreu Maria Teresa , Pearson Alex , Campbell James , Shnyder Steve D. , Knowles Margaret A. , Ashworth Alan , Turner Nicholas C.
Published: April 2023

Supplementary Figure 7 - PDF file 36K, Expression of EGFR and HGF from a publically available bladder cancer gene expression data set
Supplementary Figure 1 from Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Authors: Herrera-Abreu Maria Teresa , Pearson Alex , Campbell James , Shnyder Steve D. , Knowles Margaret A. , Ashworth Alan , Turner Nicholas C.
Published: April 2023

Supplementary Figure 1 - PDF file 573K, Analysis of siRNA screen results
Supplementary Figure 3 from Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma
Authors: He Lei , Torres-Lockhart Kristine , Forster Nicole , Ramakrishnan Saranya , Greninger Patricia , Garnett Mathew J. , McDermott Ultan , Rothenberg Stephen M. , Benes Cyril H. , Ellisen Leif W.
Published: April 2023

Supplementary Figure 3 PDF file 139K, FBW7 mutant cancer cell lines lack Mcl-1 DNA copy number increase, express higher levels of Bim and are sensitive to HDAC inhibitors
Supplementary Figure S3 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes
Authors: Chmielecki Juliann , Hutchinson Katherine E. , Frampton Garrett M. , Chalmers Zachary R. , Johnson Adrienne , Shi Chanjuan , Elvin Julia , Ali Siraj M. , Ross Jeffrey S. , Basturk Olca , Balasubramanian Sohail , Lipson Doron , Yelensky Roman , Pao William , Miller Vincent A. , Klimstra David S. , Stephens Philip J.
Published: April 2023

Supplementary Fig. S3: Co-mutation across all PACC tumors.
Supplementary Figure S2 from Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes
Authors: Chmielecki Juliann , Hutchinson Katherine E. , Frampton Garrett M. , Chalmers Zachary R. , Johnson Adrienne , Shi Chanjuan , Elvin Julia , Ali Siraj M. , Ross Jeffrey S. , Basturk Olca , Balasubramanian Sohail , Lipson Doron , Yelensky Roman , Pao William , Miller Vincent A. , Klimstra David S. , Stephens Philip J.
Published: April 2023

Supplementary Fig. S2: Loss of function mutations in select tumor suppressor genes.
Supplementary Data Figure 7 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Authors: Balko Justin M. , Giltnane Jennifer M. , Wang Kai , Schwarz Luis J. , Young Christian D. , Cook Rebecca S. , Owens Phillip , Sanders Melinda E. , Kuba Maria G. , Sánchez Violeta , Kurupi Richard , Moore Preston D. , Pinto Joseph A. , Doimi Franco D. , Gómez Henry , Horiuchi Dai , Goga Andrei , Lehmann Brian D. , Bauer Joshua A. , Pietenpol Jennifer A. , Ross Jeffrey S. , Palmer Gary A. , Yelensky Roman , Cronin Maureen , Miller Vincent A. , Stephens Phillip J. , Arteaga Carlos L.
Published: April 2023

PDF 118K, TSC1 truncation in the RD of a TNBC after NAC
Supplementary Table 1 from The p53 Target Gene SIVA Enables Non–Small Cell Lung Cancer Development
Authors: Van Nostrand Jeanine L. , Brisac Alice , Mello Stephano S. , Jacobs Suzanne B.R. , Luong Richard , Attardi Laura D.
Published: April 2023

qPCR Primer List.
Supplementary Table 1 from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Authors: Pan Rongqing , Hogdal Leah J. , Benito Juliana M. , Bucci Donna , Han Lina , Borthakur Gautam , Cortes Jorge , DeAngelo Daniel J. , Debose LaKeisha , Mu Hong , Döhner Hartmut , Gaidzik Verena I. , Galinsky Ilene , Golfman Leonard S. , Haferlach Torsten , Harutyunyan Karine G. , Hu Jianhua , Leverson Joel D. , Marcucci Guido , Müschen Markus , Newman Rachel , Park Eugene , Ruvolo Peter P. , Ruvolo Vivian , Ryan Jeremy , Schindela Sonja , Zweidler-McKay Patrick , Stone Richard M. , Kantarjian Hagop , Andreeff Michael , Konopleva Marina , Letai Anthony G.
Published: April 2023

PDF file 222K, This includes the clinical characteristics of AML patients studied in this manuscript
Supplementary Methods from Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Authors: Pan Rongqing , Hogdal Leah J. , Benito Juliana M. , Bucci Donna , Han Lina , Borthakur Gautam , Cortes Jorge , DeAngelo Daniel J. , Debose LaKeisha , Mu Hong , Döhner Hartmut , Gaidzik Verena I. , Galinsky Ilene , Golfman Leonard S. , Haferlach Torsten , Harutyunyan Karine G. , Hu Jianhua , Leverson Joel D. , Marcucci Guido , Müschen Markus , Newman Rachel , Park Eugene , Ruvolo Peter P. , Ruvolo Vivian , Ryan Jeremy , Schindela Sonja , Zweidler-McKay Patrick , Stone Richard M. , Kantarjian Hagop , Andreeff Michael , Konopleva Marina , Letai Anthony G.
Published: April 2023

PDF file 86K, This includes the supplemental methods
Supplementary Figures from Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Authors: Wu Yi-Mi , Su Fengyun , Kalyana-Sundaram Shanker , Khazanov Nickolay , Ateeq Bushra , Cao Xuhong , Lonigro Robert J. , Vats Pankaj , Wang Rui , Lin Su-Fang , Cheng Ann-Joy , Kunju Lakshmi P. , Siddiqui Javed , Tomlins Scott A. , Wyngaard Peter , Sadis Seth , Roychowdhury Sameek , Hussain Maha H. , Feng Felix Y. , Zalupski Mark M. , Talpaz Moshe , Pienta Kenneth J. , Rhodes Daniel R. , Robinson Dan R. , Chinnaiyan Arul M.
Published: April 2023

Supplementary Figures - PDF file 639K, Supplementary Figures S1-S9 show the phenotypic effects and signaling pathways of FGFR fusions in vitro and in vivo
Supplementary Figure S3 from Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Authors: Shern Jack F. , Chen Li , Chmielecki Juliann , Wei Jun S. , Patidar Rajesh , Rosenberg Mara , Ambrogio Lauren , Auclair Daniel , Wang Jianjun , Song Young K. , Tolman Catherine , Hurd Laura , Liao Hongling , Zhang Shile , Bogen Dominik , Brohl Andrew S. , Sindiri Sivasish , Catchpoole Daniel , Badgett Thomas , Getz Gad , Mora Jaume , Anderson James R. , Skapek Stephen X. , Barr Frederic G. , Meyerson Matthew , Hawkins Douglas S. , Khan Javed
Published: April 2023

PDF file 3294K, Germline alteration of TP53 in patient RMS212
Supplementary Table S3 from Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers
Authors: Hagerstrand Daniel , Tong Alexander , Schumacher Steven E. , Ilic Nina , Shen Rhine R. , Cheung Hiu Wing , Vazquez Francisca , Shrestha Yashaswi , Kim So Young , Giacomelli Andrew O. , Rosenbluh Joseph , Schinzel Anna C. , Spardy Nicole A. , Barbie David A. , Mermel Craig H. , Weir Barbara A. , Garraway Levi A. , Tamayo Pablo , Mesirov Jill P. , Beroukhim Rameen , Hahn William C.
Published: April 2023

Supplementary Table S3 - XLSX file 12K, Proteins that associate with TLOC1
Supplementary Table S2 from Systematic Interrogation of 3q26 Identifies TLOC1 and SKIL as Cancer Drivers
Authors: Hagerstrand Daniel , Tong Alexander , Schumacher Steven E. , Ilic Nina , Shen Rhine R. , Cheung Hiu Wing , Vazquez Francisca , Shrestha Yashaswi , Kim So Young , Giacomelli Andrew O. , Rosenbluh Joseph , Schinzel Anna C. , Spardy Nicole A. , Barbie David A. , Mermel Craig H. , Weir Barbara A. , Garraway Levi A. , Tamayo Pablo , Mesirov Jill P. , Beroukhim Rameen , Hahn William C.
Published: April 2023

Supplementary Table S2 - XLSX file 1063K, Gene list derived from a gene expression based comparative marker selection between cell lines with normal or amplified levels of 3q26
Supplementary Table Legends, Figure Legends, Figures S1 - S6 from Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles
Authors: Kim Eejung , Ilic Nina , Shrestha Yashaswi , Zou Lihua , Kamburov Atanas , Zhu Cong , Yang Xiaoping , Lubonja Rakela , Tran Nancy , Nguyen Cindy , Lawrence Michael S. , Piccioni Federica , Bagul Mukta , Doench John G. , Chouinard Candace R. , Wu Xiaoyun , Hogstrom Larson , Natoli Ted , Tamayo Pablo , Horn Heiko , Corsello Steven M. , Lage Kasper , Root David E. , Subramanian Aravind , Golub Todd R. , Getz Gad , Boehm Jesse S. , Hahn William C.
Published: April 2023

Supplementary Figure S1. Distribution of barcode read representation in pre-expansion and pre-injection samples. Supplementary Figure S2. Tumor composition of in vivo pooled screen, excluding the pools shown in Figure 2. Supplementary Figure S3. Gene expression differentiates functional alleles. Supplementary Figure S4. Validation of rare oncogenic alleles, excluding the ones shown in Figure 4. Supplementary Figure S5. Gene expression signatures of NFE2L2 wild type and gain-offunction mutants are correlated. Supplementary Figure S6. Comparison to in silico methods.
Supplementary Figure 6 from In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K–AKT Signaling at Endosomes
Authors: Li Chew Chen , Lunardi Andrea , Gulluni Federico , Ruan Daniel T. , Chen Ming , Salmena Leonardo , Nishino Michiya , Papa Antonella , Ng Christopher , Fung Jacqueline , Clohessy John G. , Sasaki Junko , Sasaki Takehiko , Bronson Roderick T. , Hirsch Emilio , Pandolfi Pier Paolo
Published: April 2023

Supplementary Figure 6. PI3K-C2alpha regulates AKT2 signaling.
Supplementary Figure 3 from Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Authors: Kaneda Megan M. , Cappello Paola , Nguyen Abraham V. , Ralainirina Natacha , Hardamon Chanae R. , Foubert Philippe , Schmid Michael C. , Sun Ping , Mose Evangeline , Bouvet Michael , Lowy Andrew M. , Valasek Mark A. , Sasik Roman , Novelli Francesco , Hirsch Emilio , Varner Judith A.
Published: April 2023

Intravital imaging of orthotopic PDAC growth and spread.
Supplementary Figure 1 from Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression
Authors: Kaneda Megan M. , Cappello Paola , Nguyen Abraham V. , Ralainirina Natacha , Hardamon Chanae R. , Foubert Philippe , Schmid Michael C. , Sun Ping , Mose Evangeline , Bouvet Michael , Lowy Andrew M. , Valasek Mark A. , Sasik Roman , Novelli Francesco , Hirsch Emilio , Varner Judith A.
Published: April 2023

Time course of PDAC tumor inflammation.
Supplementary Figure 3 from In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K–AKT Signaling at Endosomes
Authors: Li Chew Chen , Lunardi Andrea , Gulluni Federico , Ruan Daniel T. , Chen Ming , Salmena Leonardo , Nishino Michiya , Papa Antonella , Ng Christopher , Fung Jacqueline , Clohessy John G. , Sasaki Junko , Sasaki Takehiko , Bronson Roderick T. , Hirsch Emilio , Pandolfi Pier Paolo
Published: April 2023

Supplementary Figure 3. INPP4B's promoter is not directly methylated.
Supplementary Figure 2 from In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K–AKT Signaling at Endosomes
Authors: Li Chew Chen , Lunardi Andrea , Gulluni Federico , Ruan Daniel T. , Chen Ming , Salmena Leonardo , Nishino Michiya , Papa Antonella , Ng Christopher , Fung Jacqueline , Clohessy John G. , Sasaki Junko , Sasaki Takehiko , Bronson Roderick T. , Hirsch Emilio , Pandolfi Pier Paolo
Published: April 2023

Supplementary Figure 2. Validation of INPP4B antibody.
Supplementary Table S1 from Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Authors: de Bono Johann , Ramanathan Ramesh K. , Mina Lida , Chugh Rashmi , Glaspy John , Rafii Saeed , Kaye Stan , Sachdev Jasgit , Heymach John , Smith David C. , Henshaw Joshua W. , Herriott Ashleigh , Patterson Miranda , Curtin Nicola J. , Byers Lauren Averett , Wainberg Zev A.
Published: April 2023

Supplementary Table S1. Dose-response and exposure-response parameters.
Supplementary Table S4 from DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia
Authors: Meyer Sara E. , Qin Tingting , Muench David E. , Masuda Kohei , Venkatasubramanian Meenakshi , Orr Emily , Suarez Lauren , Gore Steven D. , Delwel Ruud , Paietta Elisabeth , Tallman Martin S. , Fernandez Hugo , Melnick Ari , Le Beau Michelle M. , Kogan Scott , Salomonis Nathan , Figueroa Maria E. , Grimes H. Leighton
Published: April 2023

RNA-Seq gene expression analyses of Flt3ITD/ITD;Dnmt3afl/fl MxCre AML versus Flt3ITD/ITD;Dnmt3afl/fl MPN and comparison of differentially expressed genes to human FLT3-ITD/DNMT3A-mut gene expression and murine AML DMR by GSEA. Lists of AML-unique and HSPC-like genes in human and mouse based on deregulated gene expression found only in the Dnmt3a mutant AML groups or deregulated gene expression in Dnmt3a mutant AML with similar deregulation patterns to normal HSC.
Supplementary Table S6 from Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube
Authors: Eckert Mark A. , Pan Shawn , Hernandez Kyle M. , Loth Rachel M. , Andrade Jorge , Volchenboum Samuel L. , Faber Pieter , Montag Anthony , Lastra Ricardo , Peter Marcus E. , Yamada S. Diane , Lengyel Ernst
Published: April 2023

Core amplifications and deletions.
Supplementary Table 4 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Authors: Sadanandam Anguraj , Wullschleger Stephan , Lyssiotis Costas A. , Grötzinger Carsten , Barbi Stefano , Bersani Samantha , Körner Jan , Wafy Ismael , Mafficini Andrea , Lawlor Rita T. , Simbolo Michele , Asara John M. , Bläker Hendrik , Cantley Lewis C. , Wiedenmann Bertram , Scarpa Aldo , Hanahan Douglas
Published: April 2023

Supplementary Table 4 contains list of primer sequence used for qRT-PCR analysis.
Supplementary Table 3 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Authors: Sadanandam Anguraj , Wullschleger Stephan , Lyssiotis Costas A. , Grötzinger Carsten , Barbi Stefano , Bersani Samantha , Körner Jan , Wafy Ismael , Mafficini Andrea , Lawlor Rita T. , Simbolo Michele , Asara John M. , Bläker Hendrik , Cantley Lewis C. , Wiedenmann Bertram , Scarpa Aldo , Hanahan Douglas
Published: April 2023

Supplementary Table 3 includes two worksheets - a) evaluation of insulin and Enpp2 IHC staining of human PanNET TMA and b) protein expression levels determined by global proteomic analysis of mouse PanNET samples.
Supplementary Table 2 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Authors: Sadanandam Anguraj , Wullschleger Stephan , Lyssiotis Costas A. , Grötzinger Carsten , Barbi Stefano , Bersani Samantha , Körner Jan , Wafy Ismael , Mafficini Andrea , Lawlor Rita T. , Simbolo Michele , Asara John M. , Bläker Hendrik , Cantley Lewis C. , Wiedenmann Bertram , Scarpa Aldo , Hanahan Douglas
Published: April 2023

Supplementary Table 2 contains patient and tumor characteristics of the core clinical samples used in the miR and mRNA profiling.
Supplementary Table 1 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Authors: Sadanandam Anguraj , Wullschleger Stephan , Lyssiotis Costas A. , Grötzinger Carsten , Barbi Stefano , Bersani Samantha , Körner Jan , Wafy Ismael , Mafficini Andrea , Lawlor Rita T. , Simbolo Michele , Asara John M. , Bläker Hendrik , Cantley Lewis C. , Wiedenmann Bertram , Scarpa Aldo , Hanahan Douglas
Published: April 2023

Supplementary Table 1 contains underlying data from microRNA and mRNA transcriptome profiling of human and mouse PanNET samples associated with the main and supplementary figures and can be found in different worksheets.
Supplementary Figures S1 - S3, Tables S1 - S6 from Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Authors: Russo Mariangela , Siravegna Giulia , Blaszkowsky Lawrence S. , Corti Giorgio , Crisafulli Giovanni , Ahronian Leanne G. , Mussolin Benedetta , Kwak Eunice L. , Buscarino Michela , Lazzari Luca , Valtorta Emanuele , Truini Mauro , Jessop Nicholas A. , Robinson Hayley E. , Hong Theodore S. , Mino-Kenudson Mari , Di Nicolantonio Federica , Thabet Ashraf , Sartore-Bianchi Andrea , Siena Salvatore , Iafrate A. John , Bardelli Alberto , Corcoran Ryan B.
Published: April 2023

Supplementary Figure S1. MEK1 K57 mutation confers resistance to anti-EGFR antibodies in CRC preclinical models. Supplementary Figure S2. Dual blockade of EGFR and MEK restores sensitivity to CRC cells expressing MEK1 K57N or K57T. Supplementary Figure S3. Longitudinal analysis of founder mutations in patient plasma during panitumumab and trametinib treatment. Supplementary Table S1. 1000 gene sequencing panel. Supplementary Table S2. 40 gene targeted sequencing panel. Supplementary Table S3. Summary of targeted sequencing and ddPCR data on tissue specimens. Supplementary Table S4. Next generation sequencing data from plasma ctDNA. Supplementary Table S5. Summary of serial ctDNA analyses. Supplementary Table S6. Ratio of resistance-associated genetic alterations and founder mutations in serial plasma ctDNA timepoints.
Supplementary Figures 1 - 6 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics
Authors: Sadanandam Anguraj , Wullschleger Stephan , Lyssiotis Costas A. , Grötzinger Carsten , Barbi Stefano , Bersani Samantha , Körner Jan , Wafy Ismael , Mafficini Andrea , Lawlor Rita T. , Simbolo Michele , Asara John M. , Bläker Hendrik , Cantley Lewis C. , Wiedenmann Bertram , Scarpa Aldo , Hanahan Douglas
Published: April 2023

Supplementary Figure 1. NMF analysis of PanNET miR expression and its validation. Supplementary Figure 2. NMF analysis of PanNET gene expression and its validation. Supplementary Figure 3. Cross-species analysis of gene expression subtypes in human and mouse PanNETs. Supplementary Figure 4. ENPP2 and INS mRNA expression in human PanNET subtypes as assessed using human PanNET core clinical gene expression microarray dataset. Supplementary Figure 5. Comparison of mouse PanNET subtypes to microdissected invasive IT vs. non-invasive IC2 of mouse PanNET tumors: Relationship to PanNET histotypes and progenitor gene signatures. Supplementary Figure 6. Metabolic profiles of IT and MLP cell lines.
Supplementary Table S7 from Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Authors: Johanns Tanner M. , Miller Christopher A. , Dorward Ian G. , Tsien Christina , Chang Edward , Perry Arie , Uppaluri Ravindra , Ferguson Cole , Schmidt Robert E. , Dahiya Sonika , Ansstas George , Mardis Elaine R. , Dunn Gavin P.
Published: April 2023

Predicted neoantigens generated as described above. This table contains all peptides with predicted ic50 less than 500 and fold-change greater than 1. The list is provided before filtering for expression or presence in the founding clone.
Supplementary Table S1: Sample mutations from Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist
Authors: McKeown Michael R. , Corces M. Ryan , Eaton Matthew L. , Fiore Chris , Lee Emily , Lopez Jeremy T. , Chen Mei Wei , Smith Darren , Chan Steven M. , Koenig Julie L. , Austgen Kathryn , Guenther Matthew G. , Orlando David A. , Lovén Jakob , Fritz Christian C. , Majeti Ravindra
Published: April 2023

Patient sample features including cytogenetic alterations and mutations
Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Authors: Chen Pei-Ling , Roh Whijae , Reuben Alexandre , Cooper Zachary A. , Spencer Christine N. , Prieto Peter A. , Miller John P. , Bassett Roland L. , Gopalakrishnan Vancheswaran , Wani Khalida , De Macedo Mariana Petaccia , Austin-Breneman Jacob L. , Jiang Hong , Chang Qing , Reddy Sangeetha M. , Chen Wei-Shen , Tetzlaff Michael T. , Broaddus Russell J. , Davies Michael A. , Gershenwald Jeffrey E. , Haydu Lauren , Lazar Alexander J. , Patel Sapna P. , Hwu Patrick , Hwu Wen-Jen , Diab Adi , Glitza Isabella C. , Woodman Scott E. , Vence Luis M. , Wistuba Ignacio I. , Amaria Rodabe N. , Kwong Lawrence N. , Prieto Victor , Davis R. Eric , Ma Wencai , Overwijk Willem W. , Sharpe Arlene H. , Hu Jianhua , Futreal P. Andrew , Blando Jorge , Sharma Padmanee , Allison James P. , Chin Lynda , Wargo Jennifer A.
Published: April 2023

Supplementary Figure 1. Immune profiling of pre-treatment, on-treatment and progression CTLA-4 blockade samples by immunohistochemistry. Supplementary Figure 2. Myeloid cell profiling of pre-treatment, on-treatment and progression CTLA-4 blockade samples by immunohistochemistry. Supplementary Figure 3. Increased contact between CD8 T cells and CD68 myeloid cells in non-responding patients to anti-CTLA-4 and anti-PD-1 therapy at pre-treatment CTLA-4 blockade, pre-treatment PD-1 blockade, and on-treatment PD-1 blockade time points. Supplementary Figure 4. Immune profiling of pre anti-PD-1, on-treatment anti-PD-1 and progression anti-PD-1 samples by immunohistochemistry. Supplementary Figure 5. Longitudinal increase in CD8, PD-1, and PD-L1 expression in responders to anti-PD-1 therapy. Supplementary Figure 6. Relative increase in CD8 T cell infiltrate at tumor center in responders to anti-PD-1 on treatment. Supplementary Figure 7. Significant increase in immune infiltrate between responders and non-responders to PD-1 blockade in absence of prior anti-CTLA-4 therapy. Supplementary Figure 8. Immune profiling of myeloid cells atpre-treatment and on-treatment PD-1 blockade time pointsby immunohistochemistry. Supplementary Figure 9. Heatmap of 54 NanoString samples. Supplementary Figure 10. Gene-specific NanoString concordance with immune profiling by IHC in pre-treatment, on-treatment and progression CTLA-4 blockade samples. Supplementary Figure 11. Gene-specific NanoString concordance with immune profiling by IHC in pre-treatment, on-treatment and progression PD-1 blockade samples. Supplementary Figure 12. Prior CTLA-4 blockade is not required for PD-1 early on-treatment profile. Supplementary Figure 13. Hierarchical clustering of gene expression across 54 samples confirms lack of batch effect.
Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
Authors: Chen Pei-Ling , Roh Whijae , Reuben Alexandre , Cooper Zachary A. , Spencer Christine N. , Prieto Peter A. , Miller John P. , Bassett Roland L. , Gopalakrishnan Vancheswaran , Wani Khalida , De Macedo Mariana Petaccia , Austin-Breneman Jacob L. , Jiang Hong , Chang Qing , Reddy Sangeetha M. , Chen Wei-Shen , Tetzlaff Michael T. , Broaddus Russell J. , Davies Michael A. , Gershenwald Jeffrey E. , Haydu Lauren , Lazar Alexander J. , Patel Sapna P. , Hwu Patrick , Hwu Wen-Jen , Diab Adi , Glitza Isabella C. , Woodman Scott E. , Vence Luis M. , Wistuba Ignacio I. , Amaria Rodabe N. , Kwong Lawrence N. , Prieto Victor , Davis R. Eric , Ma Wencai , Overwijk Willem W. , Sharpe Arlene H. , Hu Jianhua , Futreal P. Andrew , Blando Jorge , Sharma Padmanee , Allison James P. , Chin Lynda , Wargo Jennifer A.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 3 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Authors: Sánchez-Paulete Alfonso R. , Cueto Francisco J. , Martínez-López María , Labiano Sara , Morales-Kastresana Aizea , Rodríguez-Ruiz María E. , Jure-Kunkel Maria , Azpilikueta Arantza , Aznar M. Angela , Quetglas José I. , Sancho David , Melero Ignacio
Published: April 2023

Systemic sFlt3L and local intratumoral poly-ICLC expand and mature DCs in B16-OVA bearing mice.
Supplementary Figure 1 from Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
Authors: Tricker Erin M. , Xu Chunxiao , Uddin Sharmeen , Capelletti Marzia , Ercan Dalia , Ogino Atsuko , Pratilas Christine A. , Rosen Neal , Gray Nathanael S. , Wong Kwok-Kin , Jänne Pasi A.
Published: April 2023

Supplementary Figure S1. Trametinib sensitivity of EGFR mutant NSCLC cell lines and inhibition of ERK dependent genes. (A) Inhibition of ERK1/2 was assessed in each cell line after 8 hours of treatment followed by immunoblot for total and phosphorylated ERK1/2. Hsp90 was used as a loading control. (B) The viability of PC9, HCC4006, HCC2279 and HCC2935 cells was assessed after 72 hours. (C) PC9 GR4 (EGFR Del746_A750/T790M) cells were treated with DMSO (Media), 100 nM WZ4002, 30 nM trametinib or a combination thereof for 8 hours or (D) 24 hours and ERK1/2 dependent gene transcription was assessed by quantitative PCR, asterisk, p < 0.05 by one-tailed t-test.
Figures S1-7 from Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
Authors: Haricharan Svasti , Punturi Nindo , Singh Purba , Holloway Kimberly R. , Anurag Meenakshi , Schmelz Jacob , Schmidt Cheryl , Lei Jonathan T. , Suman Vera , Hunt Kelly , Olson John A. , Hoog Jeremy , Li Shunqiang , Huang Shixia , Edwards Dean P. , Kavuri Shyam M. , Bainbridge Matthew N. , Ma Cynthia X. , Ellis Matthew J.
Published: April 2023

Supplementary Figure 1 Mismatch repair dysregulation associates with high mutation load and poor clinical outcome in patients with ER breast cancer. Supplementary Figure 2 MutL complex disruption in ER breast cancer cells induces endocrine therapy resistance. Supplementary Figure 3 Spontaneously MutL-deficient ER breast cancer cells are endocrine therapy resistant. Supplementary Figure 4 MutL deficient cells induce endocrine therapy resistance via Chk2. Supplementary Figure 5 Chk2 activation is required for response to endocrine therapy in ER breast cancer cells. Supplementary Figure 6 Chk2 activation is sufficient to sensitize MutL proficient ER breast cancer cells to endocrine therapy. Supplementary Figure 7 MutL deficient ER breast cancer cells can be sensitized to endocrine treatment by combinatorial administration of CDK4/6 inhibitors.
Supplementary Table S2 from Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus–Host Protein Network
Authors: Eckhardt Manon , Zhang Wei , Gross Andrew M. , Von Dollen John , Johnson Jeffrey R. , Franks-Skiba Kathleen E. , Swaney Danielle L. , Johnson Tasha L. , Jang Gwendolyn M. , Shah Priya S. , Brand Toni M. , Archambault Jacques , Kreisberg Jason F. , Grandis Jennifer R. , Ideker Trey , Krogan Nevan J.
Published: April 2023

MiST Scores for all HPV-Human PPIs. Related to Figures 1 and 2.
Supplementary Methods from Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Authors: Eskiocak Banu , McMillan Elizabeth A. , Mendiratta Saurabh , Kollipara Rahul K. , Zhang Hailei , Humphries Caroline G. , Wang Changguang , Garcia-Rodriguez Jose , Ding Ming , Zaman Aubhishek , Rosales Tracy I. , Eskiocak Ugur , Smith Michael P. , Sudderth Jessica , Komurov Kakajan , Deberardinis Ralph J. , Wellbrock Claudia , Davies Michael A. , Wargo Jennifer A. , Yu Yonghao , De Brabander Jef K. , Williams Noelle S. , Chin Lynda , Rizos Helen , Long Georgina V. , Kittler Ralf , White Michael A.
Published: April 2023

Extended Experimental Methods
Supplementary Figure S6 from Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Authors: Chonghaile Triona Ni , Roderick Justine E. , Glenfield Cian , Ryan Jeremy , Sallan Stephen E. , Silverman Lewis B. , Loh Mignon L. , Hunger Stephen P. , Wood Brent , DeAngelo Daniel J. , Stone Richard , Harris Marian , Gutierrez Alejandro , Kelliher Michelle A. , Letai Anthony
Published: April 2023

NSG mice were injected in the tail with either ETP-ALL (TALL-x-11) or typical T-ALL (TALL-x-2) 1X106 cells and following engraftment to 65% the mice were randomized to receive vehicle, ABT-199 or ABT-263 treatment for two-weeks. The spleen weights (A) and absolute human CD45+ counts (B) along with % human CD45+ cell in the blood (C) were measured for the ETP-ALL primagraft following treatment. The leg bones were harvested and representative images are shown for the different treatments (D). Similar experiments were performed for the typical T-ALL primagraft spleen weights (E), absolute human CD45+ count in the spleen (F) with % human CD45+ cells in the blood were measured (G). Similarly the legs bones were harvested and representative images are shown (H).
Supplementary Table 4 from The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis
Authors: Goddard Erica T. , Hill Ryan C. , Nemkov Travis , D'Alessandro Angelo , Hansen Kirk C. , Maller Ori , Mongoue-Tchokote Solange , Mori Motomi , Partridge Ann H. , Borges Virginia F. , Schedin Pepper
Published: April 2023

University of Colorado Young Women's Breast Cancer Cohort patient statistics.
Supplementary Table 2 from The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis
Authors: Goddard Erica T. , Hill Ryan C. , Nemkov Travis , D'Alessandro Angelo , Hansen Kirk C. , Maller Ori , Mongoue-Tchokote Solange , Mori Motomi , Partridge Ann H. , Borges Virginia F. , Schedin Pepper
Published: April 2023

Balb/c mouse liver metabolomics.
Supplementary Table 1 from The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis
Authors: Goddard Erica T. , Hill Ryan C. , Nemkov Travis , D'Alessandro Angelo , Hansen Kirk C. , Maller Ori , Mongoue-Tchokote Solange , Mori Motomi , Partridge Ann H. , Borges Virginia F. , Schedin Pepper
Published: April 2023

Sprague-Dawley rat liver metabolomics and ECM proteomics data.
Supplementary Methods from The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis
Authors: Goddard Erica T. , Hill Ryan C. , Nemkov Travis , D'Alessandro Angelo , Hansen Kirk C. , Maller Ori , Mongoue-Tchokote Solange , Mori Motomi , Partridge Ann H. , Borges Virginia F. , Schedin Pepper
Published: April 2023

Supplementary Methods
Supplementary Figures 1 - 7 from The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis
Authors: Goddard Erica T. , Hill Ryan C. , Nemkov Travis , D'Alessandro Angelo , Hansen Kirk C. , Maller Ori , Mongoue-Tchokote Solange , Mori Motomi , Partridge Ann H. , Borges Virginia F. , Schedin Pepper
Published: April 2023

Supplementary Figure 1. Liver expansion and regression during pregnancy and weaning suggest weaning-induced liver involution. Supplementary Figure 2. Cycle of ECM remodeling in the rodent liver across reproductive stages. Supplementary Figure 3. ECM remodeling during weaning-induced liver involution occurs in the absence of overt fibrosis. Supplementary Figure 4. Weaning-induced liver involution in the mouse. Supplementary Figure 5. Myeloid cell populations increase in abundance and form foci during weaning-induced liver involution in rodents. Supplementary Figure 6. Detection of liver metastases using multi-color immunofluorescence. Supplementary Figure 7. Weaning-induced liver involution supports increased seeding but not outgrowth compared to nulliparous and regressed livers.
Supplementary Figure S2 from PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition
Authors: Mathur Deepti , Stratikopoulos Elias , Ozturk Sait , Steinbach Nicole , Pegno Sarah , Schoenfeld Sarah , Yong Raymund , Murty Vundavalli V. , Asara John M. , Cantley Lewis C. , Parsons Ramon
Published: April 2023

Supplementary Figure S2. Pyrimidine synthesis is upregulated in Pten-/- MEFs.
Table S3 from First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Authors: Sullivan Ryan J. , Infante Jeffrey R. , Janku Filip , Wong Deborah Jean Lee , Sosman Jeffrey A. , Keedy Vicki , Patel Manish R. , Shapiro Geoffrey I. , Mier James W. , Tolcher Anthony W. , Wang-Gillam Andrea , Sznol Mario , Flaherty Keith , Buchbinder Elizabeth , Carvajal Richard D. , Varghese Anna M. , Lacouture Mario E. , Ribas Antoni , Patel Sapna P. , DeCrescenzo Gary A. , Emery Caroline M. , Groover Anna L. , Saha Saurabh , Varterasian Mary , Welsch Dean J. , Hyman David M. , Li Bob T.
Published: April 2023

Pharmacokinetic data expressed in Cmax at each dose level in the dose escalation portion of the study.
Supplementary Figure S5 from Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity
Authors: Loo Tze Mun , Kamachi Fumitaka , Watanabe Yoshihiro , Yoshimoto Shin , Kanda Hiroaki , Arai Yuriko , Nakajima-Takagi Yaeko , Iwama Atsushi , Koga Tomoaki , Sugimoto Yukihiko , Ozawa Takayuki , Nakamura Masaru , Kumagai Miho , Watashi Koichi , Taketo Makoto M. , Aoki Tomohiro , Narumiya Shuh , Oshima Masanobu , Arita Makoto , Hara Eiji , Ohtani Naoko
Published: April 2023

Supplementary Figure S5. DCA and LTA promote obesity-associated HCC.
Supplementary Figure S10 from Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity
Authors: Loo Tze Mun , Kamachi Fumitaka , Watanabe Yoshihiro , Yoshimoto Shin , Kanda Hiroaki , Arai Yuriko , Nakajima-Takagi Yaeko , Iwama Atsushi , Koga Tomoaki , Sugimoto Yukihiko , Ozawa Takayuki , Nakamura Masaru , Kumagai Miho , Watashi Koichi , Taketo Makoto M. , Aoki Tomohiro , Narumiya Shuh , Oshima Masanobu , Arita Makoto , Hara Eiji , Ohtani Naoko
Published: April 2023

Supplementary Figure S10. The representative H&E staining photographs of human NASH-associated HCC.
Supplementary_table_S4 from Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin
Authors: Yang Dian , Denny Sarah K. , Greenside Peyton G. , Chaikovsky Andrea C. , Brady Jennifer J. , Ouadah Youcef , Granja Jeffrey M. , Jahchan Nadine S. , Lim Jing Shan , Kwok Shirley , Kong Christina S. , Berghoff Anna S. , Schmitt Anna , Reinhardt H. Christian , Park Kwon-Sik , Preusser Matthias , Kundaje Anshul , Greenleaf William J. , Sage Julien , Winslow Monte M.
Published: April 2023

table_S4_gene_ontology_combined
Supplemental Data from In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma
Authors: Frank Matthew J. , Reagan Patrick M. , Bartlett Nancy L. , Gordon Leo I. , Friedberg Jonathan W. , Czerwinski Debra K. , Long Steven R. , Hoppe Richard T. , Janssen Robert , Candia Albert F. , Coffman Robert L. , Levy Ronald
Published: April 2023

Supplemental Tables T1-T3, and Supplemental Figures S1-S5
Supplementary Material from A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis
Authors: Ajona Daniel , Ortiz-Espinosa Sergio , Moreno Haritz , Lozano Teresa , Pajares María J. , Agorreta Jackeline , Bértolo Cristina , Lasarte Juan J. , Vicent Silvestre , Hoehlig Kai , Vater Axel , Lecanda Fernando , Montuenga Luis M. , Pio Ruben
Published: April 2023

Supplementary Methods: For the characterization of the L-aptamer AON-D21 Supplementary Results: Characterization of the L-aptamer AON-D21 Supplementary References Supplementary Figure S1: Pharmacokinetics of AON-D21 Supplementary Figure S2: Individual follow up of subcutaneous growth and rechallenge Supplementary Figure S3: Splenic leukocyte subpopulations in mice bearing 393P tumors Supplementary Figure S4: Scatter plots of CD8 T cells in treated 393P tumors Supplementary Figure S5: Tumor-infiltrating leukocyte subpopulations in 393P tumors Supplementary Figure S6: Splenic leukocyte subpopulations in mice bearing LLC tumors Supplementary Figure S7: Tumor-infiltrating leukocyte subpopulations and IL2 in LLC tumors Supplementary Figure S8: Flow cytometry gating strategy Supplementary Table S1: Rate constants and dissociation constant of AON-D21 Supplementary Table S2: mRNA expression of immune-related molecules in 393P tumors
Table S9 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer
Authors: Lok Sheau W. , Whittle James R. , Vaillant François , Teh Charis E. , Lo Louisa L. , Policheni Antonia N. , Bergin Alice R.T. , Desai Jayesh , Ftouni Sarah , Gandolfo Luke C. , Liew Danny , Liu He K. , Mann G. Bruce , Moodie Kate , Murugasu Anand , Pal Bhupinder , Roberts Andrew W. , Rosenthal Mark A. , Shackleton Kylie , Silva Maria João , Siow Zhen R. , Smyth Gordon K. , Taylor Leanne , Travers Avraham , Yeo Belinda , Yeung Miriam M. , Bujak Andjelija Zivanovic , Dawson Sarah-Jane , Gray Daniel H.D. , Visvader Jane E. , Lindeman Geoffrey J.
Published: April 2023

Supplementary Table S9
Supplementary Table 1 from A Stromal Lysolipid–Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression
Authors: Auciello Francesca R. , Bulusu Vinay , Oon Chet , Tait-Mulder Jacqueline , Berry Mark , Bhattacharyya Sohinee , Tumanov Sergey , Allen-Petersen Brittany L. , Link Jason , Kendsersky Nicholas D. , Vringer Esmee , Schug Michelle , Novo David , Hwang Rosa F. , Evans Ronald M. , Nixon Colin , Dorrell Craig , Morton Jennifer P. , Norman Jim C. , Sears Rosalie C. , Kamphorst Jurre J. , Sherman Mara H.
Published: April 2023

Table S1
Supplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
Authors: Dudley Jonathan C. , Schroers-Martin Joseph , Lazzareschi Daniel V. , Shi William Y. , Chen Simon B. , Esfahani Mohammad S. , Trivedi Dharati , Chabon Jacob J. , Chaudhuri Aadel A. , Stehr Henning , Liu Chih Long , Lim Harumi , Costa Helio A. , Nabet Barzin Y. , Sin Mandy L.Y. , Liao Joseph C. , Alizadeh Ash A. , Diehn Maximilian
Published: April 2023

Supplemental Figures
Supplementary Data from Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA
Authors: Dudley Jonathan C. , Schroers-Martin Joseph , Lazzareschi Daniel V. , Shi William Y. , Chen Simon B. , Esfahani Mohammad S. , Trivedi Dharati , Chabon Jacob J. , Chaudhuri Aadel A. , Stehr Henning , Liu Chih Long , Lim Harumi , Costa Helio A. , Nabet Barzin Y. , Sin Mandy L.Y. , Liao Joseph C. , Alizadeh Ash A. , Diehn Maximilian
Published: April 2023

Supplemental Tables
Table S1 from Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells
Authors: Radomska Katarzyna J. , Coulpier Fanny , Gresset Aurelie , Schmitt Alain , Debbiche Amal , Lemoine Sophie , Wolkenstein Pierre , Vallat Jean-Michel , Charnay Patrick , Topilko Piotr
Published: April 2023

Tumour phenotypes in Prss56Cre, R26tdTom, Nf1flox/flox and Prss56Cre, R26tdTom, Nf1flox/- mice
Supplementary Materials and Methods from Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells
Authors: Radomska Katarzyna J. , Coulpier Fanny , Gresset Aurelie , Schmitt Alain , Debbiche Amal , Lemoine Sophie , Wolkenstein Pierre , Vallat Jean-Michel , Charnay Patrick , Topilko Piotr
Published: April 2023

Supplementary Materials and Methods
Supplementary Table S3 from Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Authors: Oser Matthew G. , Fonseca Raquel , Chakraborty Abhishek A. , Brough Rachel , Spektor Alexander , Jennings Rebecca B. , Flaifel Abdallah , Novak Jesse S. , Gulati Aditi , Buss Elizabeth , Younger Scott T. , McBrayer Samuel K. , Cowley Glenn S. , Bonal Dennis M. , Nguyen Quang-De , Brulle-Soumare Laura , Taylor Paula , Cairo Stefano , Ryan Colm J. , Pease Elizabeth J. , Maratea Kim , Travers Jon , Root David E. , Signoretti Sabina , Pellman David , Ashton Susan , Lord Christopher J. , Barry Simon T. , Kaelin William G.
Published: April 2023

Supplementary Table S3 shows enrichment analysis from our screen analyzed using RIGER-E Log Fold Change 2nd Best algorithm.
Supplementary Figures S1-S6 from Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells
Authors: Radomska Katarzyna J. , Coulpier Fanny , Gresset Aurelie , Schmitt Alain , Debbiche Amal , Lemoine Sophie , Wolkenstein Pierre , Vallat Jean-Michel , Charnay Patrick , Topilko Piotr
Published: April 2023

Supplementary Figures S1-S6